Shelley Hall, MD
Advanced Heart Failure and Transplant Cardiology · Dallas, TXNPI 1912961145
Payments from drug & device makers
Across 538 payments — averaging $2442.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$831K
- Novartis$207K
- American Regent$70K
- Veloxis Pharmaceuticals, Inc.$59K
- Cvrx, Inc.$49K
- Abiomed$32K
- plus $65K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 336 | $831,467 |
| Novartis | 35 | $207,352 |
| American Regent | 20 | $69,899 |
| Veloxis Pharmaceuticals, Inc. | 2 | $58,917 |
| Cvrx, Inc. | 61 | $49,353 |
| Abiomed | 24 | $32,164 |
| Actelion Pharmaceuticals, Ltd | 14 | $30,089 |
| Sanofi US Services Inc. | 5 | $15,595 |
| Medtronic(2 entities) | 18 | $11,051 |
| Sanofi-aventis U.S. LLC | 2 | $6,709 |
| Heartflow, Inc. | 1 | $350 |
| Atricure, Inc. | 2 | $201 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $184 |
| Alnylam Pharmaceuticals Inc. | 3 | $150 |
| Ancora Heart, Inc. | 1 | $132 |
| ZOLL Respicardia, Inc. | 2 | $101 |
| Merck | 2 | $97 |
| Amgen | 1 | $22 |
| Briohealth Solutions, Inc. | 1 | $20 |
| Nuwellis, Inc. | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| AbbVie | 1 | $12 |
How this compares
$1,313,949 in reported general payments places this provider in the 90th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in Dallas
- Robert GottliebDallas$14.1M
- Martin BerkDallas$1.9M
- Elizabeth HardinDallas$571K
- Claudius MahrDallas$331K
- Maryjane FarrDallas$304K
- Katherine MichelisDallas$187K
- Kartik TelukuntlaDallas$80K
- Song LiDallas$27K
- Farah Al-SaffarDallas$24K
- Srikant PatlollaDallas$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.